Germany's financial regulator BaFin has denied futurum bank AG's application for a crypto-asset service provider license under the EU's MiCAR rules, impacting Bitcoin Group SE's bitcoin.de platform. The application was submitted in June 2025, but trading on bitcoin.de has been mostly inactive since June 12, 2026, due to the ongoing licensing process. Bitcoin Group is considering filing an objection and exploring a new operating model involving two regulated German institutions to resume trading on bitcoin.de.
The BaFin rejection of Bitcoin Group's MiCAR license application comes as a backdrop to a broad downturn in major cryptocurrencies on Pluang. For readers following this story, here is Pluang's market snapshot as of Oct 07, 2026 09:21 WIB: out of 50 major cryptocurrencies, 44 fell and only 5 rose today. Notable movers include ZIL (Zilliqa) down 7.13% at Rp60 with a typical hold time of 133 days and a Pluang order activity of 28% Sell / 72% Buy, FIL (Filecoin) down 6.62% at Rp19,565, and BAT (Basic Attention Token) down 5.97% at Rp1,775.
The Reserve Bank of India raised its key policy rate by 25 basis points to 5.5%, marking the first increase since 2023. This move aims to curb rising inflation, which has been increasing for 10 consecutive months and currently stands above the RBI's ...
Temasek, Singapore's state-owned investment firm, sees the biggest market risk as a potential reversal in the artificial intelligence (AI) trade, which currently supports U.S. stock highs despite rising Treasury yields. Factors like tighter regulatio...
On October 6, U.S. spot Bitcoin ETFs attracted $118.8 million in net inflows, driven mainly by IBIT which contributed $122 million, making it the largest positive inflow among Bitcoin ETFs. In contrast, Ethereum ETFs experienced $201.9 million in net...
Abstract, an Ethereum layer-2 blockchain focused on consumer applications, will shut down on December 15 after its parent company Igloo lost tens of millions of dollars funding it. Despite processing over 325 million transactions and hosting $6 billi...
Palindrome Pharma, a new Canadian pharmaceutical company, has launched with a focus on biosimilar medicines to improve access to biologic therapies and support a sustainable healthcare system. The company aims to build a diverse portfolio through par...
